Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder
Conditions
Interventions
Cannabidiol oral solution
Cannabidiol oral solution
+1 more
Locations
17
United States
EPI-CBD-001 Site
Encino, California, United States
EPI-CBD-001 Site
Lemon Grove, California, United States
EPI-CBD-001 Site
Los Alamitos, California, United States
EPI-CBD-001-Site
Oceanside, California, United States
EPI-CBD-001 site
San Jose, California, United States
EPI-CBD-001 Site
Jacksonville, Florida, United States
Start Date
October 27, 2022
Primary Completion Date
December 13, 2023
Completion Date
December 13, 2023
Last Updated
November 21, 2024
NCT07456631
NCT06661460
NCT06678295
NCT05858346
NCT07323784
NCT06845488
Lead Sponsor
EmpowerPharm Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions